Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ttRNA-LPA vaccine
- Development stage
- Unknown
- Lead developer
- University of Florida
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
The ttRNA-LPA vaccine is an mRNA-based therapeutic vaccine designed for cancer treatment. It utilizes multi-lamellar RNA lipid-particle aggregates (RNA-LPAs) as a delivery system for messenger RNA (mRNA). This mRNA is often derived from a patient's own tumor, allowing for a highly personalized approach. The vaccine's mechanism involves delivering tumor-specific mRNA to cells, leading to the expression of tumor antigens. This process aims to reprogram the tumor microenvironment from an 'immune-cold' to an 'immune-hot' state, thereby eliciting a robust adaptive immune response against cancer cells. Developed by the University of Florida, this vaccine has shown promising results in preclinical studies and early human trials for indications such as glioblastoma and rhabdomyosarcoma.
- Other names
- RNA-LPA vaccinemRNA-LPA vaccinemulti-lamellar RNA lipid-particle aggregates
Beyond the preview
Go deeper on ttRNA-LPA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ttRNA-LPA vaccine.